Regimen Reference Order – BRST – eriBULin mesylate

ARIA: BRST – [eriBULin]

Planned Course: **Every 21 days until disease progression or unacceptable toxicity**
Indication for Use: **Breast Cancer Metastatic**

CVAD: At Provider's Discretion

Proceed with treatment if:
ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 75 x 10^9/L
- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – eriBULin mesylate

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1 and 8		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
eriBULin mesylate	1.4 mg/m^2	IV in normal saline 50 mL over 5 minutes *Use non-DEHP bags*

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See BRST DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Cardiac monitoring
- EKG at baseline then as clinically indicated

All Cycles
Day 1
- CBC, biochemistry, liver enzymes and total bilirubin as per Physician Orders

Day 8
- CBC

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- eriBULin mesylate can cause neuropathy
- eriBULin mesylate can cause QTc interval prolongation